Janus Kinases, antagonists & inhibitors
- Name
- Janus Kinases, antagonists & inhibitors
- Accession Number
- DBCAT001908
- Description
Not Available
- Drugs
Drug Drug Description Ruxolitinib A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. Tofacitinib A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis. Oclacitinib Not Annotated Pacritinib A kinase inhibitor used for the treatment of primary and secondary myelofibrosis in adult patients with significantly reduced platelet counts. AZD-1480 AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF), and Essential Thrombocythaemia Myelofibrosis. BMS-911543 BMS-911543 has been used in trials studying the treatment of Cancer. Gandotinib Gandotinib has been used in trials studying the treatment of Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders, among others. Filgotinib A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. Ritlecitinib A kinase inhibitor used to treat severe alopecia areata in adults and adolescents 12 years and older. Abrocitinib A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. Ivarmacitinib A selective JAK1 inhibitor under investigation for the treatment of immuno-inflammatory diseases. - Drugs & Drug Targets